Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Dario Carrara"'
Autor:
Laetitia Delpy, Caroline Derne, Lee S. Simon, Inger Byrjalsen, Dario Carrara, Asger Reinstrup Bihlet
Publikováno v:
Seminars in arthritis and rheumatism. 50(6)
Purpose Osteoarthritis Research Society International (OARSI) Expert Consensus Guidelines recommend topical non-steroidal anti-inflammatory drugs as first-line medications for osteoarthritis (OA) knee pain, but several voluminous daily applications a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d9d8ad451ef922bccc6d6712df960fc
https://pubmed.ncbi.nlm.nih.gov/33059293
https://pubmed.ncbi.nlm.nih.gov/33059293
Autor:
Anders Neijber, Laurence Belkoff, Gerald B. Brock, Glenn R. Cunningham, Mitchell Efros, Masakazu Ando, Marc Gittelman, Dario Carrara, Jules T. Mitchel
Publikováno v:
Endocrine Practice. 23:557-565
Objective: Testosterone replacement therapy is indicated for male hypogonadism. This study aimed to evaluate the efficacy and safety of testosterone gel 2% (Tgel) over 90 days. Methods: This phase 3, open-label, noncomparator study was conducted in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52a3bf4c7e1f430c9bef445e12bef79b
https://doi.org/10.4158/ep161665.or
https://doi.org/10.4158/ep161665.or
Publikováno v:
Andrologia. 48:637-645
Pharmacokinetics, pharmacodynamics and safety of a novel hydroalcoholic testosterone gel 2% (TG) were evaluated in phase II sequential dose escalation studies using 3 application sites (thigh, abdomen and shoulder/upper arm) and 2 application methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e61536b75de9077c7c8a140599aed22e
https://doi.org/10.1111/and.12493
https://doi.org/10.1111/and.12493
Publikováno v:
Clinical Pharmacology in Drug Development. 3:358-364
This randomized, open-label, multiple-dose three-way cross-over study compared the pharmacokinetics of a new testosterone gel formulation in two strengths, testosterone gel 1% and testosterone gel 2% (FE 999303), with Testogel® in 11 testosterone-su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7819d80405423f0a24b5ee7b6de93e6
https://doi.org/10.1002/cpdd.110
https://doi.org/10.1002/cpdd.110
Autor:
Judith M. Schloss Markowitz, Jules T. Mitchel, Mitchell D. Efros, Joonhyuk Choi, Kerri Weingard, Dario Carrara, Vadim Tantsyura, Dean Gittleman, Yong Joong Kim, Hua (Helen) Yin, Timothy Cho
Publikováno v:
Drug Information Journal. 46:464-471
In order to assess the impact of direct data entry (DDE) on the clinical trial process, a single-site, phase 2 clinical trial, under a US investigational new drug application (IND), was performed where the clinical site entered each subject’s data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1b6947cf41bf01aff53533235cf7c26
https://doi.org/10.1177/0092861512449530
https://doi.org/10.1177/0092861512449530
Publikováno v:
Andrologia. 50:e12801
Efficacy and safety of testosterone gel 2% (TG) were evaluated in two phase 3, open-labelled, single-arm, multicentre studies (000023 and extension study 000077). Hypogonadal men having serum testosterone levels300 ng/dl at two consecutive measuremen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::049593e6d85f48207d7f0eee18211a44
https://doi.org/10.1111/and.12801
https://doi.org/10.1111/and.12801
Publikováno v:
Clinical pharmacology in drug development. 3(5)
This randomized, open-label, multiple-dose three-way cross-over study compared the pharmacokinetics of a new testosterone gel formulation in two strengths, testosterone gel 1% and testosterone gel 2% (FE 999303), with Testogel® in 11 testosterone-su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::909924c7d1e1af09c5a544f44d39deb8
https://pubmed.ncbi.nlm.nih.gov/31368673
https://pubmed.ncbi.nlm.nih.gov/31368673